Assessment of safety and effectiveness of oral morphine on patients attending pain and palliative care: a study on Indian population
| Autor: | Nikhil John Abraham, Sunitha Daniel, K N Anila, Sreelakshmi Jayan, Stephy Stephen, Kevin Tom Koshy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Palliative care non cancer Pharmacology toxicology Pharmacy Biochemistry 03 medical and health sciences 0302 clinical medicine 030502 gerontology medicine cancer pain Oral morphine Molecular Biology Pharmacology palliative care business.industry Indian population opioids morphine General Medicine 030220 oncology & carcinogenesis Family medicine Medicine 0305 other medical science business |
| Zdroj: | Current Issues in Pharmacy and Medical Sciences, Vol 33, Iss 4, Pp 184-190 (2020) |
| ISSN: | 2300-6676 |
| Popis: | Opioid analgesics remain the corner stone of effective management of moderate to severe pain. Morphine in its oral and parenteral form is one of the most affordable options left to treat severe cancer pain in most Palliative centres in India. The main objective of our study was to assess the safety and effectiveness, as well as the prescribing pattern of immediate release oral morphine on the Indian population attending Pain and Palliative Care in a multi-speciality hospital. Within the sample population, 74.8% of all patients achieved a pain score reduction of less than or equal to 3 within the 72nd hour. Although the mean baseline pain score was similar in the cancer (8.23±0.75) and the non-cancer (8.26±0.98) group, the mean pain score at the 24th and 72nd hours were significantly different (5.6±1.29 in cancer and 5.09±1.26 in the non-cancer group within the 24th hour, followed by 3.66±1.479 and 3.12±0.88 after the 72nd hour, respectively). The majority of the patients (58.3%) were prescribed at a frequency of 5 mg every 4th hourly, with double dose at bedtime. A similar prescribing trend was seen in both the cancer and non-cancer groups. Moreover, 14 patients underwent dose escalation – with 12 belonging to the cancer group, while 11 patients falling under the cancer group required a switch to different therapy. The major adverse drug reactions (ADR) observed in both study groups were constipation (89.2%), fatigue (37.4%), dry mouth (36%) and nausea/vomiting (23%). The severity of nausea/vomiting and sleepiness was higher in the cancer group whereas itching was more predominant among the non-cancer group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|